Clinical trial
Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
NCT05250817 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 9, 2021
- Completion date
- January 4, 2023
- Enrollment
- 501 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.